Diurnal sells rights to cortisol deficiency drugs in Israel

2 March 2017
diurnal-large

UK-based Diurnal (AIM: DNL) has reached an agreement with Medison Pharma over the commercialization of Infacort (hydrocortisone) and Chronocort (hydrocortisone) in Israel.

Under the terms of the agreement, Medison will receive the exclusive rights to market and sell the treatments in Israel. Shares in Diurnal are up over 3% today.

Infacort, the first preparation of hydrocortisone designed for use in children suffering from adrenal insufficiency, was submitted for market authorization to the European Medicines Agency in late 2016.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical